RAPP
Rapport Therapeutics, Inc. Common Stock · Healthcare · Biotechnology
Momentum-inputs (vergelijkbare managers):
breedte van houders +12.5% ·
aandelenstroom +3.6% ·
netto nieuwe posities +11.1%
— formule
Brede accumulatie — stijgende aandelen bij meer houders
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q2 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 69 | +3 | 25.15M | $1.04B | +5 | −2 |
| Q1 2026 | 69 | +1 | 25.07M | $783.61M | +5 | −4 |
| Q4 2025 | 68 | +1 | 25.43M | $771.51M | +1 | — |
| Q3 2025 | 16 | +4 | 15.68M | $465.84M | +4 | — |
| Q2 2025 | 9 | +1 | 10.01M | $113.83M | +2 | −1 |
| Q1 2025 | 5 | 0 | 1.86M | $18.69M | +1 | −1 |
| Q4 2024 | 5 | 0 | 2.06M | $36.50M | — | — |
| Q3 2024 | 4 | -2 | 1.81M | $36.50M | +1 | −3 |
| Q2 2024 | 6 | — | 2.18M | $50.21M | — | — |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 5.47M | — | $62.25M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Fidelity (FMR) ✦ | 5.47M | — | $62.25M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | T. Rowe Price ✦ | 1.53M | +42.1% | $17.35M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 4 | T. Rowe Price ✦ | 1.53M | +42.1% | $17.35M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 5 | BlackRock ✦ (passief) | 1.22M | — | $13.86M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | BlackRock ✦ (passief) | 1.22M | — | $13.86M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | BlackRock ✦ (passief) | 1.22M | — | $13.86M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | BlackRock ✦ (passief) | 1.22M | — | $13.86M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | BlackRock ✦ (passief) | 1.22M | — | $13.86M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | BlackRock ✦ (passief) | 1.22M | — | $13.86M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | BlackRock ✦ (passief) | 1.22M | — | $13.86M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | The Vanguard Group ✦ (passief) | 1.11M | — | $12.59M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | The Vanguard Group ✦ (passief) | 1.11M | — | $12.59M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | The Vanguard Group ✦ (passief) | 1.11M | — | $12.59M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Geode Capital Management ✦ (passief) | 333.16K | +5.5% | $3.79M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 16 | Geode Capital Management ✦ (passief) | 333.16K | +5.5% | $3.79M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 17 | State Street Global Advisors ✦ (passief) | 298.71K | +56.3% | $3.40M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 18 | Two Sigma Investments ✦ | 19.74K | -41.5% | $224,478 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 19 | AQR Capital Management ✦ | 16.97K | Nieuw | $192,971 | 0.0% | New | 1 | SEC ↗ |
| 20 | AQR Capital Management ✦ | 16.97K | Nieuw | $192,971 | 0.0% | New | 1 | SEC ↗ |
| 21 | AQR Capital Management ✦ | 16.97K | Nieuw | $192,971 | 0.0% | New | 1 | SEC ↗ |
| 22 | AQR Capital Management ✦ | 16.97K | Nieuw | $192,971 | 0.0% | New | 1 | SEC ↗ |
| 23 | Renaissance Technologies ✦ | 15.60K | Nieuw | $177,372 | 0.0% | New | 1 | SEC ↗ |
"Hun gewicht" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die beheerder — de overtuigingsmaatstaf. ✦ = gecureerde beheerder.
Nieuwe kopers
| AQR Capital Management | $192,971 | 0.0% |
| AQR Capital Management | $192,971 | 0.0% |
| AQR Capital Management | $192,971 | 0.0% |
| AQR Capital Management | $192,971 | 0.0% |
| Renaissance Technologies | $177,372 | 0.0% |
Verlaten
| Citadel Advisors | $2.50M | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 146 houders, 52.47M aandelen, $1.59B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect verder het vaakst bezitten — aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer · 404 aand · $20,160
Officer, Director · 3.66K aand · $171,837
Officer, Director · 19.50K aand · $936,846
Officer, Director · 5.79K aand · $281,721
Officer, Director · 14.17K aand · $651,492
Officer, Director · 8.37K aand · $391,280
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie